Drug Profile
Varespladib - Ophirex
Alternative Names: A-001; A-002; LY-315920; LY-333013; Methyl-varespladib; S-3013; S-5920; Varespladib methylLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Shionogi
- Developer Anthera Pharmaceuticals; Ophirex; University Health Network
- Class Acetic acids; Anti-inflammatories; Antirheumatics; Indoles; Small molecules
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections; Snake venom poisoning
- Discontinued Acute coronary syndromes; Acute lung injury; Coronary artery disease; Multiple organ failure; Systemic inflammatory response syndrome
Most Recent Events
- 10 Jan 2023 Varespladib receives Fast track status from the US FDA for Snake venom poisoning
- 05 Jan 2023 Ophirex completes enrolment in the phase II BRAVO trial for Snake venom poisoning in India and US (NCT04996264)
- 22 Nov 2022 Ophirex terminates the phase II STAIRS clinical trial in COVID-2019 infections in USA, due to slow enrollment resulting from decrease in infection rate (PO) (NCT04969991)